RT Journal Article
SR Electronic
T1 Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.24.20075291
DO 10.1101/2020.04.24.20075291
A1 Christian Erikstrup
A1 Christoffer Egeberg Hother
A1 Ole Birger Vestager Pedersen
A1 Kåre Mølbak
A1 Robert Leo Skov
A1 Dorte Kinggaard Holm
A1 Susanne Sækmose
A1 Anna Christine Nilsson
A1 Patrick Terrence Brooks
A1 Jens Kjærgaard Boldsen
A1 Christina Mikkelsen
A1 Mikkel Gybel-Brask
A1 Erik Sørensen
A1 Khoa Manh Dinh
A1 Susan Mikkelsen
A1 Bjarne Kuno Møller
A1 Thure Haunstrup
A1 Lene Harritshøj
A1 Bitten Aagaard Jensen
A1 Henrik Hjalgrim
A1 Søren Thue Lillevang
A1 Henrik Ullum
YR 2020
UL http://medrxiv.org/content/early/2020/04/28/2020.04.24.20075291.abstract
AB Background The pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has tremendous consequences for our societies. Knowledge of the seroprevalence of SARS-CoV-2 is needed to accurately monitor the spread of the epidemic and also to calculate the infection fatality rate (IFR). These measures may help the authorities to make informed decisions and adjust the current societal interventions. Blood donors comprise approximately 4.7% of the similarly aged population of Denmark and blood is donated in all areas of the country. The objective of this study was to perform real-time seroprevalence surveying among blood donors as a tool to estimate previous SARS-CoV-2 infections and the population based IFR.Methods All Danish blood donors aged 17-69 years giving blood April 6 to 17 were tested for SARS-CoV-2 immunoglobulin M and G antibodies using a commercial lateral flow test. Antibody status was compared between areas and an estimate of the IFR was calculated. The seroprevalence was adjusted for assay sensitivity and specificity taking the uncertainties of the test validation into account when reporting the 95% confidence intervals (CI).Results The first 9,496 blood donors were tested and a combined adjusted seroprevalence of 1.7% (CI: 0.9-2.3) was calculated. The seroprevalence differed across areas. Using available data on fatalities and population numbers a combined IFR in patients younger than 70 is estimated at 82 per 100,000 (CI: 59-154) infections.Conclusions The IFR was estimated to be slightly lower than previously reported from other countries not using seroprevalence data. The IFR, including only individuals with no comorbidity, is likely several fold lower than the current estimate. This may have implications for risk mitigation. We have initiated real-time nationwide anti-SARS-CoV-2 seroprevalence surveying of blood donations as a tool in monitoring the epidemic.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols http://www.bloddonor.dk/antisarscov2 Funding StatementThe project was performed in kind of the participating institutions.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAggregated data are available. Please see provided URL.